Evolus, Inc. (FRA:EVL)
Germany
· Delayed Price · Currency is EUR 5.75
+0.05 (0.88%)
At close: Dec 5, 2025
Evolus Company Description
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.
It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels.
The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Evolus, Inc.
| Country | United States |
| Founded | 2012 |
| Industry | Pharmaceutical Preparations |
| Employees | 332 |
| CEO | David Moatazedi |
Contact Details
Address: 520 Newport Center Drive Newport Beach, Delaware 92660 United States | |
| Phone | 949 284 4555 |
| Website | evolus.com |
Stock Details
| Ticker Symbol | EVL |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Moatazedi | Chief Executive Officer |
| Tatjana Mitchell | Chief Financial Officer |
| Nareg Sagherian | Head of Investor Relations |